The US Food and Drug Administration recently expanded the approved indications for spinal cord stimulators marketed by Medtronic and Nevro.
On 19 January, the FDA approved a “panel track” premarket approval supplement for Nevro’s Senza line of high-frequency 10 kHz (HFX) spinal cord stimulation (SCS) systems to treat non-surgical...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?